DE69736598T2 - Ribonukleaseresistente rna präparation und seine verwendung - Google Patents

Ribonukleaseresistente rna präparation und seine verwendung Download PDF

Info

Publication number
DE69736598T2
DE69736598T2 DE69736598T DE69736598T DE69736598T2 DE 69736598 T2 DE69736598 T2 DE 69736598T2 DE 69736598 T DE69736598 T DE 69736598T DE 69736598 T DE69736598 T DE 69736598T DE 69736598 T2 DE69736598 T2 DE 69736598T2
Authority
DE
Germany
Prior art keywords
rna
sequence
bacteriophage
rna molecule
standard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736598T
Other languages
German (de)
English (en)
Other versions
DE69736598D1 (de
Inventor
B. Dwight Austin DUBOIS
M. Matthew Austin WINKLER
L. Brittan Austin PASLOSKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenetron Diagnostics Austin Tex Us LLC
Asuragen Inc
Original Assignee
Cenetron Diagnostics Austin LLC
Ambion Inc
Cenetron Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/675,153 external-priority patent/US5677124A/en
Application filed by Cenetron Diagnostics Austin LLC, Ambion Inc, Cenetron Diagnostics LLC filed Critical Cenetron Diagnostics Austin LLC
Publication of DE69736598D1 publication Critical patent/DE69736598D1/de
Application granted granted Critical
Publication of DE69736598T2 publication Critical patent/DE69736598T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/34011—Potyviridae
    • C12N2770/34022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/34011—Potyviridae
    • C12N2770/34023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/34011—Potyviridae
    • C12N2770/34041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/34042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69736598T 1996-07-03 1997-07-02 Ribonukleaseresistente rna präparation und seine verwendung Expired - Lifetime DE69736598T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US2114596P 1996-07-03 1996-07-03
US21145P 1996-07-03
US08/675,153 US5677124A (en) 1996-07-03 1996-07-03 Ribonuclease resistant viral RNA standards
US675153 1996-07-03
US881571 1997-06-24
US08/881,571 US5939262A (en) 1996-07-03 1997-06-24 Ribonuclease resistant RNA preparation and utilization
PCT/US1997/012551 WO1998000547A1 (en) 1996-07-03 1997-07-02 Ribonuclease resistant rna preparation and utilization

Publications (2)

Publication Number Publication Date
DE69736598D1 DE69736598D1 (de) 2006-10-12
DE69736598T2 true DE69736598T2 (de) 2007-08-09

Family

ID=26694321

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736598T Expired - Lifetime DE69736598T2 (de) 1996-07-03 1997-07-02 Ribonukleaseresistente rna präparation und seine verwendung

Country Status (8)

Country Link
US (5) US5939262A (https=)
EP (1) EP0910643B1 (https=)
JP (2) JP4315471B2 (https=)
AT (1) ATE338127T1 (https=)
AU (1) AU729601B2 (https=)
CA (1) CA2258485C (https=)
DE (1) DE69736598T2 (https=)
WO (1) WO1998000547A1 (https=)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939262A (en) * 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
DE19737442C2 (de) * 1997-08-22 1999-06-24 Olfert Landt Tib Molbiol Synth Proteinumhüllte Polyribonukleinsäuren, ein Verfahren zu ihrer Herstellung und ihre Verwendung
EP1892299A3 (en) * 1997-09-19 2011-07-20 Life Technologies Corporation Sense mRNA therapy
US20030083272A1 (en) * 1997-09-19 2003-05-01 Lahive & Cockfield, Llp Sense mrna therapy
US7767422B2 (en) * 1998-09-22 2010-08-03 Oncomedx, Inc. Detection of 5T4 RNA in plasma and serum
US6777210B1 (en) * 1998-09-24 2004-08-17 Ambion, Inc. Method and reagents for inactivating ribonucleases RNase A, RNase I and RNase T1
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
KR20000065690A (ko) * 1999-04-08 2000-11-15 박종구 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
ES2253358T3 (es) * 2000-03-31 2006-06-01 Cambridge Antibody Technology Limited Mejoras en la visualizacion del ribosoma.
EP1354060B1 (en) * 2000-08-28 2011-02-09 Oncomedx, Inc. 5t4 rna in plasma and serum as a marker for neoplastic disease
GB0021303D0 (en) * 2000-08-30 2000-10-18 Medinnova Sf Use
RU2189396C2 (ru) * 2000-10-27 2002-09-20 Федеральное государственное учреждение науки и здравоохранения Нижегородский научно-исследовательский институт эпидемиологии и микробиологии им. акад. И.Н.Блохиной Способ обнаружения и дифференциации рнк энтеровирусов
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20020172972A1 (en) * 2001-05-15 2002-11-21 President And Fellows Of Harvard College Use of a selectively inactivatable enzyme to digest contaminating nucleic acid
CN1311084C (zh) * 2001-12-06 2007-04-18 阿隆戴蒙德艾滋病研究中心 利用嵌合噬菌体标准物的高灵敏基因组检测
EP2290098A1 (en) 2002-01-28 2011-03-02 Ambion, Inc. Preparing crude biological extracts using protease, suitable for preparing cDNA
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP2213737B1 (en) 2002-02-01 2012-11-07 Life Technologies Corporation Double-stranded oligonucleotides
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
WO2003103605A2 (en) * 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
WO2004085611A2 (en) * 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
DE602004030114D1 (de) * 2003-05-20 2010-12-30 Investigen Inc System zum nachweis von polynukleotiden
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
DE602004026912D1 (de) * 2003-12-16 2010-06-10 Qiagen North American Holdings Formulierungen und verfahren zum denaturieren von proteinen
WO2005097817A2 (en) * 2004-04-05 2005-10-20 Alnylam Pharmaceuticals, Inc. Process and reagents for oligonucleotide synthesis and purification
AU2005325262B2 (en) 2004-04-27 2011-08-11 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
US7674778B2 (en) * 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
CA2572151A1 (en) 2004-06-30 2006-08-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
AU2005328382C1 (en) 2004-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
CA2574603C (en) 2004-08-04 2014-11-04 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
EP2309269B1 (en) 2004-09-08 2016-10-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for the detection of HIV-1/HIV-2 infection.
WO2006045591A2 (en) * 2004-10-25 2006-05-04 Devgen N.V. Method and constructs for delivering double stranded rna to pest organisms
JP5390772B2 (ja) 2004-11-05 2014-01-15 キアゲン ノース アメリカン ホールディングス， インコーポレイテッド 核酸を安定化試薬から精製するための組成物および方法
JP2009501531A (ja) * 2005-07-15 2009-01-22 アプレラ コーポレイション Ｒｎａプロファイリングのための方法
WO2007100711A2 (en) * 2006-02-24 2007-09-07 Investigen, Inc. Methods and compositions for detecting polynucleotides
US20100099149A1 (en) 2006-10-06 2010-04-22 Dna Genotek Inc. Stabilizing compositions and methods for extraction of ribonucleic acid
WO2008051817A1 (en) * 2006-10-20 2008-05-02 Novartis Ag Compositions and method for monitoring bcr-abl expression
US20080096193A1 (en) * 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
CN101173252B (zh) * 2006-10-31 2011-09-21 杭州市疾病预防控制中心 披甲rna及其制备方法
WO2008103702A2 (en) * 2007-02-23 2008-08-28 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
WO2009151697A2 (en) * 2008-03-14 2009-12-17 The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and processes relating to human bocavirus
US8324149B2 (en) * 2008-11-18 2012-12-04 The Board Of Trustees Of The Leland Stanford Junior University Encapsidation of heterologous entities into virus-like particles
US20100129902A1 (en) 2008-11-24 2010-05-27 Erhard Ralf Schoenbrunner Replication Stable and RNase Resistant Chimeras of Pestivirus with Insertion in 3' Nontranslated Region (3'NTR)
EP2367954B1 (en) * 2008-12-19 2015-02-18 Life Technologies Corporation Proteinase k inhibitors, methods and compositions therefor
JP6121591B2 (ja) * 2010-07-29 2017-04-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 微生物核酸の定性的および定量的検出
US8877464B2 (en) 2010-07-29 2014-11-04 Roche Molecular Systems, Inc. Qualitative and quantitative detection of microbial nucleic acids
CN103154269A (zh) 2010-07-29 2013-06-12 霍夫曼-拉罗奇有限公司 用于多种参数的对照核酸
CN103025891A (zh) 2010-07-29 2013-04-03 霍夫曼-拉罗奇有限公司 通用样品制备
ES2605303T3 (es) * 2010-07-29 2017-03-13 F. Hoffmann-La Roche Ag Detección cualitativa y cuantitativa de ácidos nucleicos microbianos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2426222A1 (en) 2010-09-07 2012-03-07 F. Hoffmann-La Roche AG Generic buffer for amplification
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2465945A1 (en) 2010-12-17 2012-06-20 F. Hoffmann-La Roche AG Generic matrix for control nucleic acids
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN106442039B (zh) 2011-06-19 2020-08-07 阿博根公司 用于样品采集的装置、溶液和方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
EP2825639B1 (en) 2012-03-13 2017-10-25 EMD Millipore Corporation Use of centrifugation-aided infection to increase virus titer
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US9481903B2 (en) 2013-03-13 2016-11-01 Roche Molecular Systems, Inc. Systems and methods for detection of cells using engineered transduction particles
KR102127358B1 (ko) 2013-03-13 2020-06-29 지니위브 바이오사이언시스, 인코포레이티드 비-복제 형질도입 입자 및 형질도입 입자-기반 리포터 시스템
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
US9540675B2 (en) 2013-10-29 2017-01-10 GeneWeave Biosciences, Inc. Reagent cartridge and methods for detection of cells
EP3105343A1 (en) * 2014-02-10 2016-12-21 AmpTec GmbH Incoated rna
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
GB201412316D0 (en) * 2014-07-10 2014-08-27 Momentum Bioscience Ltd Detecting the absence of micro-organisms
JP6822974B2 (ja) 2015-05-29 2021-01-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ シトラコン酸無水物によって微生物を不活性化する方法
US10351893B2 (en) 2015-10-05 2019-07-16 GeneWeave Biosciences, Inc. Reagent cartridge for detection of cells
US20180320199A1 (en) 2015-10-28 2018-11-08 Life Science Inkubator Gmbh Use of vlp for the detection of nucleic acids
US10689689B2 (en) * 2015-12-28 2020-06-23 Roche Molecular Systems, Inc. Generic method for the stabilization of specific RNA
US20170356025A1 (en) 2016-06-14 2017-12-14 Roche Molecular Systems, Inc. Internal control probes for improving pcr assay performance
EP3299471B1 (en) 2016-09-23 2019-10-23 Roche Diagniostics GmbH Methods for determining the amount of a nucleic acid of interest in an unprocessed sample
US10422012B2 (en) 2016-10-10 2019-09-24 Roche Molecular Systems, Inc. Devices comprising bacteriophage PHI6 internal control compositions
ES2944360T3 (es) 2017-10-03 2023-06-20 Abbott Molecular Inc Ensayo para la detección del virus de la inmunodeficiencia humana (VIH)
CN110892082A (zh) 2017-10-03 2020-03-17 雅培分子公司 丙型肝炎病毒(hcv)的测定
WO2019139792A1 (en) 2018-01-09 2019-07-18 Abbott Molecular Inc. Assay for detecting chlamydia trachomatis, neisseria gonorrhoeae, trichomonas vaginalis, and mycoplasma genitalium
WO2022045009A1 (ja) * 2020-08-24 2022-03-03 国立大学法人山口大学 流体を追跡するための組成物及び流体の追跡方法
CN115896243A (zh) * 2022-11-25 2023-04-04 上海厦维医学检验实验室有限公司 基于混合酶体系的超灵敏反转录方法及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866167A (en) * 1985-03-01 1989-09-12 Biotechnica Diagnostics, Inc. Detection of human oral cells by nucleic acid hybridization
CA1288073C (en) * 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
GB8608850D0 (en) * 1986-04-11 1986-05-14 Diatech Ltd Packaging system
ATE108828T1 (de) * 1987-02-09 1994-08-15 Lubrizol Genetics Inc Hybrides rns-virus.
US5316931A (en) * 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
EP0596979B1 (en) * 1991-08-01 2002-01-30 Large Scale Biology Corporation Recombinant plant viral nucleic acids
ATE257860T1 (de) * 1991-08-02 2004-01-15 Biomerieux Bv Quantifikation von nukleinsäuren
EP0672754B1 (en) * 1992-03-31 2004-05-19 Kanebo Ltd. Plant virus vector, plasmid, method of expressing foreign gene, and method of acquiring foreign gene product
US5443969A (en) * 1992-10-29 1995-08-22 Rutgers University RNA packaging system
GB9311386D0 (en) * 1993-06-02 1993-07-21 Pna Diagnostics As Nucleic acid analogue assay procedures
US5614413A (en) * 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
CA2125344A1 (en) * 1993-07-01 1995-01-02 Casey D. Morrow Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
ATE178946T1 (de) * 1993-07-09 1999-04-15 Akzo Nobel Nv Verbessertes verfahren für die quantifizierung von nukleinsäuren
WO1995014109A1 (en) * 1993-11-19 1995-05-26 U.S. Department Of The Army High through-put quantitative polymerase chain reaction for hiv clinical specimens
GB2285445A (en) * 1993-12-06 1995-07-12 Pna Diagnostics As Protecting nucleic acids and methods of analysis
US5824507A (en) * 1994-05-20 1998-10-20 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
AU692792B2 (en) * 1994-06-10 1998-06-18 Georgetown University Recombinant virus and related method of quantitating same
US6613749B1 (en) * 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US5736388A (en) * 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US5939262A (en) * 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
EP1194588A2 (en) 1999-04-20 2002-04-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Diagnostic standards for virus detection and quantification

Also Published As

Publication number Publication date
JP4315471B2 (ja) 2009-08-19
EP0910643B1 (en) 2006-08-30
CA2258485A1 (en) 1998-01-08
CA2258485C (en) 2013-01-29
US5939262A (en) 1999-08-17
US6214982B1 (en) 2001-04-10
US6399307B1 (en) 2002-06-04
EP0910643A1 (en) 1999-04-28
US20060257889A1 (en) 2006-11-16
DE69736598D1 (de) 2006-10-12
JP2002514905A (ja) 2002-05-21
WO1998000547A1 (en) 1998-01-08
ATE338127T1 (de) 2006-09-15
US7033749B2 (en) 2006-04-25
US20020192689A1 (en) 2002-12-19
AU3670997A (en) 1998-01-21
JP2009131272A (ja) 2009-06-18
AU729601B2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
DE69736598T2 (de) Ribonukleaseresistente rna präparation und seine verwendung
US5677124A (en) Ribonuclease resistant viral RNA standards
AU2020294216B2 (en) Methods of detection and removal of rhabdoviruses from cell lines
DE69021575T3 (de) Expressionssysteme für rekombinante negativstrang-rna-viren und impfstoffe.
Villagrana-Escareño et al. VLPs derived from the CCMV plant virus can directly transfect and deliver heterologous genes for translation into mammalian cells
DE69434931T2 (de) Methode zur selektiven inaktivierung der viralen replication
CN109475646A (zh) 用于crispr/cas成分的脂质纳米颗粒制剂
US10513542B2 (en) Minicircle DNA vector vaccine platform for foot-and-mouth disease and methods thereof
CN101970645B (zh) 呼肠弧病毒家族病毒的疫苗病毒株的制造方法
AU2021293245A1 (en) Methods of identifying and characterizing anelloviruses and uses thereof
US10221399B2 (en) In vitro reconstituted plant virus capsids for delivering RNA genes to mammalian cells
DE19737442C2 (de) Proteinumhüllte Polyribonukleinsäuren, ein Verfahren zu ihrer Herstellung und ihre Verwendung
CN1253138A (zh) 治疗丙型肝炎病毒相关性疾病的反义寡核苷酸的结构与用途
Davey Filamentous phage derived biological nanorods: development of a novel display system: a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Microbiology at Massey University, Manawatū, New Zealand
CN118834277A (zh) 慢病毒包膜蛋白、其编码核酸分子和包括其的重组慢病毒
CN119162129A (zh) 共表达高斯荧光素酶与绿色荧光蛋白的重组非洲猪瘟病毒株及其应用
Long Evaluating catalytic introns in mammalian cells for potential therapeutic application
Leibowitz et al. Factors Determining Translational Efficiency of mRNA in Yeast
Molineux Translocation and specific cleavage of bacteriophage T7 DNA in vivo by EcoKI

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AMBION, INC., AUSTIN, TEX., US

Owner name: CENETRON DIAGNOSTICS LLC, AUSTIN, TEX., US

8328 Change in the person/name/address of the agent

Representative=s name: DEHMEL & BETTENHAUSEN, PATENTANWAELTE, 80331 MUENCHEN

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASURAGEN, INC., AUSTIN, TEX., US

Owner name: CENETRON DIAGNOSTICS LLC, AUSTIN, TEX., US